Table 2.

Summary of reported cases of ANCA vasculitis after SARS-CoV-2 vaccination.

Reference	Age/sex	Vaccine (doses)	ANCA	Organ involvement	Treatment	Outcome
Anderegg et al. [6]	81 y/female	mRNA-1273 Moderna (2)	PR3	Kidney, lung	Steroids, CYC, TPE	Recovery
Sekar et al. [7]	52 y/male	mRNA-1273 Moderna (2)	PR3	Kidney	Steroids, rituximab, CYC, hemodialysis	Chronic hemodialysis
Shakoor et al. [8]	78 y/female	BNT162b2 mRNA Pfizer-BioNTech (2)	MPO	Kidney	Steroids, rituximab	Recovery
Villa et al. [9]	63 y/male	AZD1222 Oxford-AstraZeneca (1)	MPO	Kindey, lung	Steroids, CYC	Recovery
Patient 1	54 y/female	BNT162b2 mRNA Pfizer-BioNTech (2)	MPO	Kidney, lung	Steroids, rituximab	Recovery
Patient 2	78 y/female	BNT162b2 mRNA Pfizer-BioNTech (2)	MPO	Kidney	Steroids, rituximab, hemodialysis	Chronic hemodialysis

CYC, cyclophosphamide; TPE, therapeutic plasma exchange.